StockWatch
·

Parmax Pharma Ltd Q1 FY26 Results

PARMAXQ1 FY26 Results
Filing
MetricValue ( Cr)vs Q4 FY25
Revenue1.9459.8%
Total Income1.9558.8%
Expenditure2.7150.2%
PBT-0.7657.4%
Net Profit-0.7648.9%
OPM-12.87%21.06pp
NPM-39.23%7.61pp
EPS2.0449.0%
View full financials

Informational and educational content only. Not investment advice.